Literature DB >> 24029514

Physical Activity Line: effective knowledge translation of evidence-based best practice in the real-world setting.

Shannon S D Bredin1, Darren E R Warburton.   

Abstract

Mesh：

Year:  2013        PMID： 24029514      PMCID： PMC3771727     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  10 in total

Review 1.  From best evidence to best practice: effective implementation of change in patients' care.

Authors:  Richard Grol; Jeremy Grimshaw
Journal:  Lancet       Date:  2003-10-11       Impact factor: 79.321

2.  How can research organizations more effectively transfer research knowledge to decision makers?

Authors:  John N Lavis; Dave Robertson; Jennifer M Woodside; Christopher B McLeod; Julia Abelson
Journal:  Milbank Q       Date:  2003       Impact factor: 4.911

3.  Reflections on knowledge brokering within a multidisciplinary research team.

Authors:  Robin Urquhart; Geoffrey A Porter; Eva Grunfeld
Journal:  J Contin Educ Health Prof       Date:  2011       Impact factor: 1.355

4.  Arthritis, osteoporosis, and low back pain: evidence-based clinical risk assessment for physical activity and exercise clearance.

Authors:  Jamie Burr; Roy Shephard; Stephen Cornish; Hassanali Vatanparast; Philip Chilibeck
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

Review 5.  Prediabetes and type 2 diabetes mellitus: assessing risks for physical activity clearance and prescription.

Authors:  Jamie F Burr; Roy J Shephard; Michael C Riddell
Journal:  Can Fam Physician       Date:  2012-03       Impact factor: 3.275

6.  Effective synthesized/preappraised evidence formats in emergency medicine and the use of supplemental knowledge translation techniques.

Authors:  Brian H Rowe; Barry Diner; Carlos A Camargo; Andrew Worster; Antoinette Colacone; Peter C Wyer
Journal:  Acad Emerg Med       Date:  2007-11       Impact factor: 3.451

Review 7.  Physical activity in type 1 diabetes mellitus: assessing risks for physical activity clearance and prescription.

Authors:  Jamie F Burr; Roy J Shephard; Michael C Riddell
Journal:  Can Fam Physician       Date:  2012-05       Impact factor: 3.275

Review 8.  Evidence-based risk assessment and recommendations for physical activity clearance: Consensus Document 2011.

Authors:  Darren E R Warburton; Norman Gledhill; Veronica K Jamnik; Shannon S D Bredin; Don C McKenzie; James Stone; Sarah Charlesworth; Roy J Shephard
Journal:  Appl Physiol Nutr Metab       Date:  2011-07       Impact factor: 2.665

9.  Self-management and biomedical outcomes of a cooking, and exercise program for patients with chronic kidney disease.

Authors:  Mary Flesher; Paula Woo; Anthony Chiu; Ashley Charlebois; Darren E R Warburton; Barbara Leslie
Journal:  J Ren Nutr       Date:  2010-07-21       Impact factor: 3.655

10.  A description of a knowledge broker role implemented as part of a randomized controlled trial evaluating three knowledge translation strategies.

Authors:  Maureen Dobbins; Paula Robeson; Donna Ciliska; Steve Hanna; Roy Cameron; Linda O'Mara; Kara DeCorby; Shawna Mercer
Journal:  Implement Sci       Date:  2009-04-27       Impact factor: 7.327
  10 in total
  3 in total

1.  Health Benefits of Physical Activity: A Strengths-Based Approach.

Authors:  Darren E R Warburton; Shannon S D Bredin
Journal:  J Clin Med       Date:  2019-11-21       Impact factor: 4.241

2.  The health benefits and challenges of exercise training in persons living with schizophrenia: a pilot study.

Authors:  Shannon S D Bredin; Darren E R Warburton; Donna J Lang
Journal:  Brain Sci       Date:  2013-05-24

3.  WALK 2.0: examining the effectiveness of Web 2.0 features to increase physical activity in a 'real world' setting: an ecological trial.

Authors:  Cristina M Caperchione; Gregory S Kolt; Trevor N Savage; Richard R Rosenkranz; Anthony J Maeder; Corneel Vandelanotte; Mitch J Duncan; Anetta Van Itallie; Rhys Tague; W Kerry Mummery
Journal:  BMJ Open       Date:  2014-10-10       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.